Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (45): 8513-8517.doi: 10.3969/j.issn.1673-8225.2011.45.034

Previous Articles     Next Articles

Allogeneic hematopoietic stem cell transplantation versus immunosuppressive therapy as frontline treatment for severe aplastic anaemia

Xu Yong, Ouyang Jian, Chen Bing, Yang Yong-gong, Xu Jing-yan, Zhou Rong-fu, Zhang Qi-guo, Shao Xiao-yan, Guan Chao-yang   

  1. Department of Hematology, Nanjing Drum Tower Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing  210008, Jiangsu Province, China
  • Received:2011-04-17 Revised:2011-06-11 Online:2011-11-05 Published:2011-11-05
  • Contact: Ouyang Jian, Doctor, Chief physician, Department of Hematology, Nanjing Clinical Drum Tower Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing 210008, Jiangsu Province, China
  • About author:Xu Yong★, Master, Attending physician, Department of Hematology, Nanjing Clinical Drum Tower Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing 210008, Jiangsu Province, China fancyxyz@hotmail.com

PDF

376

Abstract:

BACKGROUND: Foreign reports have suggested that allogeneic hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy (IST) for acute severe aplastic anemia (SAA) have similar clinical effectiveness and overall survival period, but there are few reports about post-treatment quality of life and treatment costs of two different therapies.
OBJECTIVE: To summarize the outcome and survival of both HLA matched sibling donor HSCT (allo-HSCT) and IST in 23 SAA patients.
METHODS: Totally 7 patients with SAA who received allo-HSCT and 16 patients with SAA who received IST were selected from Department of Hematology, Nanjing Drum Tower Hospital from July 2004 to October 2010. Follow-up was performed every 3 months after treatment to observe the patients' survival, quality of life, cost of hospitalization and analyze the effects.
RESULTS AND CONCLUSION: The allo-HSCT therapy was better than the IST therapy in the neutrophil and platelets recovery speed, the time of transfusion, the overall response rate after 3 months and the complete response rate after 1 year (P < 0. 05). The overall survival rates of the two therapies were 86% and 81.3% respectively, which had no significant difference (P > 0.05). The quality of life was good at 1 year after treatment. There was no statistically significant difference between the two therapies in total efficacy rates, physiological state, psychological state, social relationships, and environmental condictions one year later. The costs of hospitalization between the two groups were similar.

CLC Number: